Ocugen, Inc. Common Stock OCGN

Ocugen, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias génicas para curar enfermedades de ceguera y en el desarrollo de vacunas para COVID-19. La cartera tecnológica de la compañía incluye: Vacuna COVID-19 (0.5), Plataforma de Terapia Génica Modificadora y Nuevas Terapias Biológicas para Enfermedades Retinianas. La Vacuna COVID-19 se está desarrollando, fabricando y comercializando COVAXIN para la prevención de COVID-19 en humanos en el Territorio Ocugen Covaxin. COVAXIN es un candidato a vacuna COVID-19 inactivada de virión completo y está formulado con el virus SARS-CoV-2 inactivado. La plataforma de Terapia Génica Modificadora está diseñada para enfermedades retinianas, incluyendo retinitis pigmentosa (RP), amaurosis congénita de Leber (LCA) y degeneración macular relacionada con la edad seca (AMD). Se está desarrollando OCU200, un nuevo candidato a producto biológico para tratar el edema macular diabético (DME), la retinopatía diabética (DR) y la AMD húmeda. OCU400, su primer candidato a producto desarrollado con su plataforma de terapia génica modificadora.

• GlobeNewswire Inc. 25 ago

  Ocugen to Participate in Upcoming September Investor and Industry Conferences

  Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at three major conferences in September 2026, including the Citi Biopharma Back to School Conference, H.C. Wainwright Global Investment Conference, and The Retina Society Annual Scientific Meeting. The company will showcase 12-month Phase 2 results for OCU410 gene therapy for geographic atrophy.

  

• GlobeNewswire Inc. 1 jul

  Ocugen to Participate in Upcoming July Industry Conferences

  Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at multiple upcoming conferences in July 2026, including presentations at Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and ASRS annual meeting. The company will showcase Phase 2 OCU410 results and clinical data for inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.

  

• GlobeNewswire Inc. 13 ene

  Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

  Ocugen announced a webcast on January 15, 2026 to discuss Phase 2 clinical trial data from the OCU410 ArMaDa trial, featuring leading ophthalmologists and company executives. The presentation will cover one-year follow-up data from the first half of patients treated with the modifier gene therapy for blindness diseases.

  

• GlobeNewswire Inc. 19 nov

  Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight

  The gene therapy market for ocular rare diseases is expanding rapidly, with breakthrough viral vector technologies enabling one-time, disease-modifying treatments for inherited retinal disorders. Multiple emerging therapies are expected to transform treatment options for previously untreatable eye conditions.

  

• GlobeNewswire Inc. 8 ago

  Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

  Ocugen has entered into a securities purchase agreement with Janus Henderson Investors to sell 20 million shares of common stock and warrants at $1.00 per share, expecting to raise approximately $20 million in gross proceeds.